论文部分内容阅读
目的:观察护肝片对中、晚期纤维化肝组织转化生长因子β1I型受体(Tβ1RⅠ)蛋白及其mRNA表达的影响。方法:采用125g/LCCl4诱导的大鼠肝纤维化模型,用免疫组化SP法检测大鼠肝组织Tβ1RⅠ蛋白的表达;用原位杂交检测Tβ1RⅠmRNA的表达。用MetaMorph图像分析系统对Tβ1RⅠ蛋白及mRNA的表达量进行定量分析。结果:①模型复制8周和13周,模型组的肝损伤及其纤维化分级均显著高于正常组(P<0.01),护肝片组的肝损伤及其纤维化分级均轻于模型组。②模型复制8周和13周,模型组Tβ1RⅠ蛋白及mRNA的表达均较正常组显著增多(P<0.01);其蛋白和mRNA的表达相互间均呈显著正相关(P<0.01)。③除13周Tβ1RⅠ蛋白外,护肝片均显著抑制模型复制8周和13周后纤维化肝组织Tβ1RⅠ蛋白及其mRNA的表达(P<0.01)。结论:护肝片可减轻肝组织的损伤及其纤维化程度,它可能在蛋白及mRNA双重水平上抑制TβRⅠ的表达,从而发挥抗肝纤维化作用。
Objective: To observe the effect of Hugan Pill on the expression of transforming growth factor-β1 type I receptor (Tβ1RI) protein and its mRNA in middle and late fibrotic liver tissue. METHODS: Rat hepatic fibrosis model induced by 125g/LCCl4 was used to detect the expression of Tβ1RI protein in rat liver tissue by immunohistochemical SP method. The expression of Tβ1RI mRNA was detected by in situ hybridization. The MetaMorph image analysis system was used to quantitatively analyze the expression of Tβ1RI protein and mRNA. RESULTS: 1 After 8 weeks and 13 weeks of model replication, the liver damage and fibrosis grades in the model group were significantly higher than those in the normal group (P<0.01). The liver damage and fibrosis grades in the Hugan Tablet group were lighter than those in the model group. . 2 The expression of Tβ1RI protein and mRNA in the model group was significantly higher than that in the normal group at 8 and 13 weeks of replication (P<0.01). The expression of protein and mRNA were significantly positively correlated with each other (P<0.01). 3 Except for 13 weeks T β 1 RI protein, Hugan Tablets significantly inhibited the expression of Tβ 1 RI protein and mRNA in the fibrotic liver tissue after 8 and 13 weeks of model replication (P<0.01). Conclusion: Hugan Tablet can reduce the degree of hepatic injury and fibrosis. It may inhibit the expression of TβR I on the dual level of protein and mRNA and exert anti-fibrosis effect.